Inovio Pharmaceuticals discussed progress on DNA medicine platform development in Q3 2024, focusing on INO-3107 for RRP treatment. Positive immunology data, regulatory discussions, and financial discipline were highlighted. Plans for BLA submission, commercialization, and pipeline advancement were emphasized.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing